Literature DB >> 11325364

How risky is early intramedullary nailing of femoral fractures in polytraumatized patients?

F Kutscha-Lissberg1, F K Hopf, E Kollig, G Muhr.   

Abstract

There is controversy over both the time of intervention and the technique of surgical stabilisation of femoral fractures in polytraumatized patients. Retrospective analysis of data on 55 such patients revealed that stabilisation within the first 24 h using locked, unreamed nails had no negative impact on the rate of pulmonary complications. The frequency of complications was assessed by comparing immediate intramedullary (IM) osteosynthesis with extramedullary stabilisation in patients with or without concomitant blunt thoracic trauma. Due to the small study population and discrepancies the size of subgroups, no definite statistical conclusions were possible. However, our results suggest that the frequency of complications is determined by the overall severity of injury rather than by the type of acute surgical treatment.

Entities:  

Mesh:

Year:  2001        PMID: 11325364     DOI: 10.1016/s0020-1383(00)00202-3

Source DB:  PubMed          Journal:  Injury        ISSN: 0020-1383            Impact factor:   2.586


  3 in total

1.  Two variants of fat embolism syndrome evolving in a young patient with multiple fractures.

Authors:  Mohd Yazid Bajuri; Rudy Reza Johan; Hassan Shukur
Journal:  BMJ Case Rep       Date:  2013-04-09

2.  Protocol for a randomized controlled trial on risk adapted damage control orthopedic surgery of femur shaft fractures in multiple trauma patients.

Authors:  Dieter Rixen; Eva Steinhausen; Stefan Sauerland; Rolf Lefering; Matthias Meier; Marc G Maegele; Bertil Bouillon; Edmund A M Neugebauer
Journal:  Trials       Date:  2009-08-19       Impact factor: 2.279

Review 3.  Early intramedullary nailing of femoral shaft fracture on outcomes in patients with severe chest injury: A meta-analysis.

Authors:  Meng Jiang; Changli Li; Chengla Yi; Shaotao Tang
Journal:  Sci Rep       Date:  2016-07-26       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.